DNMT3A Gene Mutation
Conditions
Keywords
CHIP, acute leukemia, Metformin, DNMT3A
Brief summary
This is a prospective, single-arm clinical study evaluating the efficacy and safety of metformin in inhibiting DNMT3A R882-driven clonal hematopoiesis (CH) in patients with acute leukemia (AL) who are in remission and under follow-up. Patients with DNMT3A R882 mutation (VAF ≥5%) will receive oral metformin for 6 months, with dosage gradually increased to 2000 mg/day. The primary endpoint is the proportion of patients with effective decline in DNMT3A R882 mutation VAF at 6 months. Secondary endpoints include VAF decline at 3 months, relapse-free survival (RFS) at 6 and 12 months, overall survival (OS), cumulative incidence of relapse (CIR), cumulative remission-phase mortality, and adverse event rates. Planned enrollment: 32 participants.
Detailed description
Clonal hematopoiesis (CHIP) involves hematopoietic stem cells (HSCs) acquiring mutations like DNMT3A R882, conferring a proliferative advantage and increasing risks of hematologic malignancies and inflammatory diseases. No effective interventions exist currently. Preclinical studies show that DNMT3A R882 mutations enhance mitochondrial respiration and oxidative phosphorylation (OXPHOS) in hematopoietic stem/progenitor cells (HSPCs), which is essential for their competitive advantage. Metformin, at clinical doses, inhibits the electron transport chain (ETC) complex I, reducing OXPHOS and selectively diminishing the advantage of mutant HSPCs. Mechanisms include restoring epigenetic stability by elevating methylation potential (SAM/SAH ratio), reversing hypomethylation in differential methylation regions (DMRs), and normalizing H3K27me3 histone modifications. In mouse and humanized models, metformin suppresses clonal expansion of DNMT3A R882 mutant cells. Based on metformin's 60-year safety profile in diabetes treatment, this study tests its potential in AL patients with persistent DNMT3A R882 CH post-remission. Metformin may reduce risks like secondary tumors and diabetes in these patients. Study intervention: Oral metformin starting at 500 mg twice daily, titrated to 500 mg three times daily or 1000 mg twice daily (or maximum tolerated dose), up to 2000 mg/day, taken with meals for 6 months. Efficacy assessment: Next-generation sequencing (NGS) for DNMT3A R882 VAF at 0, 3, and 6 months. * Major response: For VAF \>20%, absolute decline ≥10%; for VAF ≤20%, relative decline ≥50%. * Partial response: For VAF \>20%, absolute decline 5-10%; for VAF ≤20%, relative decline 25-50%. Safety monitoring: Close monitoring of liver/kidney function, especially in patients ≥60 years or with renal impairment, due to lactic acidosis risk. Data management uses electronic case report forms (eCRF). Statistical analysis includes intention-to-treat (ITT) and per-protocol (PP) sets, with Kaplan-Meier for survival, t-tests, Wilcoxon rank-sum, chi-square, and Cox proportional hazards models.
Interventions
DRUGMetformin
Start at 500 mg twice daily, titrate to 2000 mg/day for 6 months
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with acute leukemia based on bone marrow morphology, immunology, and genetics, per WHO 2022 or ICC criteria. * Patients in complete remission follow-up phase with DNMT3A R882 mutation clonal hematopoiesis, VAF ≥5%. * Age ≥14 years, any gender * Laboratory requirements (within 7 days before treatment): * Total bilirubin ≤1.5 × upper limit of normal (ULN) for age. * AST and ALT ≤2.5 × ULN for age. * Serum creatinine \<2 × ULN for age. * Cardiac enzymes \<2 × ULN for age. * Ejection fraction within normal range by echocardiogram (ECHO). * Signed informed consent: By patient (≥18 years) or legal guardian/relative (\<18 years or if beneficial for condition).
Exclusion criteria
* Patients with diabetes receiving other medications * Known allergy to metformin * Deemed unsuitable by investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of major molecular response based on the variant-allele frequency (VAF) of DNMT3A R882 mutation at 6-month follow-up | up to 6 months | An effective decline in VAF is defined as an absolute reduction of ≥10% when the baseline variant-allele frequency is greater than 20%; a relative reduction of ≥50% when the baseline variant-allele frequency is ≤20%. Variant-allele frequency is tested in bone-marrow samples via next-generation sequencing (NGS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of major molecular response based on the variant-allele frequency (VAF) of DNMT3A R882 mutation at 3-month follow-up | up to 3 months | The judgment standard for major molecular-response is consistent with the primary endpoint. VAF is detected in bone-marrow samples via next-generation sequencing (NGS). |
| Relapse-Free Survival (RFS) Rate at 6 Months | up to 6 months | — |
| Relapse-Free Survival (RFS) Rate at 12 Months | up to 12 months | Proportion of patients without relapse |
| Overall Survival (OS) Rate | Up to 12 months | Proportion of patients alive |
| Cumulative Incidence of Relapse (CIR) | Up to 12 months | Cumulative rate of relapse events |
| Cumulative Remission-Phase Mortality Rate | Up to 12 months | Cumulative rate of deaths during remission |
| Rate of Overall Response of DNMT3A R882 Mutation VAF at 3 Months | up to 3 months | — |
| Rate of Overall Response of DNMT3A R882 Mutation VAF at 6 Months | up to 6 months | — |
Countries
China
Contacts
CONTACTHui Wei, MD
Outcome results
None listed